Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

Launched by ABBVIE · Sep 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the safety and effectiveness of a medication called atogepant for preventing migraines in adults in Korea. Migraines are painful headaches that can come with symptoms like nausea and sensitivity to light and sound. In this study, about 3,000 adults who are already prescribed atogepant by their doctors will participate. The goal is to see how well this medication works in everyday clinical practice for people suffering from chronic or episodic migraines.

To be eligible for the study, participants should have migraines that fit the treatment guidelines for atogepant and must be prescribed this medication according to those guidelines. The trial will not add extra burdens to participants; they will simply continue their routine visits to their healthcare providers over the course of 12 weeks. This study is currently recruiting participants, and it’s important to note that those involved cannot be part of any other clinical research trials at the same time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
• • Participants prescribed atogepant in accordance with the approved local label.
• Exclusion Criteria:
• • Participants with any contraindication to atogepant as listed on the latest approved local label.
• • Participants currently participating in another clinical research except observational study.